Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of Loteprednol Etabonate Ophthalmic Gel, in Normal Healthy Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 6
- 主要终点
- Blood samples will be collected for the determination of loteprednol etabonate concentrations in plasma samples
研究概览
简要总结
Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of Loteprednol Etabonate Ophthalmic Gel, in Normal Healthy Volunteers
详细描述
The primary objective of this study is to evaluate the systemic pharmacokinetics (PK) of LE (loteprednol etabonate ophthalmic gel), 0.38% in normal healthy volunteer subjects at least 18 years of age and with a normal ophthalmic history. Systemic PK will be assessed in this study after a single dose and after 2 weeks of daily BID dosing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Are able to read, understand and provide written informed consent on an Informed Consent Form (ICF) approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
- •Be a non-smoking male or female at least 18 years of age on the date the ICF is signed and with the capacity to provide voluntary informed consent.
- •Be in general good health and free of any concomititant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or place the subject at increased risk during the study.
- •Be willing/able to return for all required study visits and follow instructions from the study Investigator and his/her staff.
- •Are able to self-administer eye drops or have a clinical staff member deliver the single dose of investigational product (IP) on specified study days.
- •Have a normal physical examination and clinical laboratory evaluation
排除标准
- •Have a history/presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the subject, confound the result(s) of the study, or preclude study treatment or follow-up.
- •Have any current disease or medical condition that requires medicinal therapy.
- •Have a history of drug or alcohol abuse in the last 6 months.
- •Have a positive urine screen for alcohol, amphetamines, barbiturates, benzodiazepines, cocaine (or cocaine metabolite), cannabinoids, methadone, methamphetamine, opiates and/or phencyclidine.
- •Are known to have a prior positive blood screen for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus types 1 and 2.
研究组 & 干预措施
Loteprednol Etabonate Ophthalmic Gel
Formulated LE into a gel (loteprednol etabonate ophthalmic gel, [Lotemax® gel])
干预措施: Loteprednol Etabonate Ophthalmic Gel (Drug)
结局指标
主要结局
Blood samples will be collected for the determination of loteprednol etabonate concentrations in plasma samples
时间窗: 2 weeks
次要结局
未报告次要终点